Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Scholar Rock will remove the Catalent Indiana fill-finish facility from the apitegromab BLA after the FDA classified an April site inspection as Official Action Indicated (OAI). The company will proceed with a second fill-finish facility, having submitted the required data package ahead of schedule, and confirmed that the FDA PDUFA action date remains September 30, 2026.
Key figures
- Drug Name
- apitegromab
- Pdufa date
- September 30, 2026
- Catalent inspection status
- Official Action Indicated (OAI)
- Second facility data status
- submitted in advance of agreed upon timeline
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.